40results about How to "Reduce the frequency of dosing" patented technology

The invention provides an intelligent medicine box system, which includes an intelligent medicine box and an external terminal; the intelligent medicine box includes an upper cover, a shell, a medicine cover layer, a medicine placement layer, and a circuit board; the intelligent medicine box also includes a control module , a power supply module, a display module, a detection module and a communication module; the invention also provides a control method for the intelligent medicine box system. The beneficial effects of implementing the present invention are: 1, the medicine box can be opened in multiple layers, which facilitates the replacement between the parts; Leakage occurs during the cleaning process with water and affects other electronic components of the medicine box; 3. The design of the first terminal and the second terminal enables the guardian and the person taking the medicine to know the situation of taking the medicine in time; 4. The designated indicator light flashes and monitors taking the medicine Whether the user opens the corresponding small cover, which reduces the possibility of the drug user taking the wrong drug.

The invention discloses a drug delivery system, and a preparation method and an application thereof. The drug delivery system comprises a molecular recognition part, an assembling part, a response part, a functional molecule part and an optional long-circulation part, the assembling part is connected with the response part, the molecular recognition part is connected to the response part or the assembling part, the functional molecule part is connected to the side chain, far from the response part, in the assembling part, and the long-circulation part is connected with the response part. The drug delivery system prepared through the preparation method greatly improves the molecular delivery efficiency of a drug or an imaging agent, enhances the retention time in the lesion site, improves the enrichment efficiency of the drug or a contrast agent in the lesion site, improves the bioavailability of the drug, reduces the administration frequency, improves the safety of the drug, and provides a new drug delivery idea and technical way for the bottlnecks of the clinical transformation of nano-drugs.

The invention discloses an agricultural and forestal plant protection unmanned helicopter with large load capacity. The agricultural and forestal plant protection unmanned helicopter with large load capacity comprises a rack, a transmission system, a rotor wing system, a power device, a fuel oil system, an undercarriage, a fairing, a flight control system, a data chain system, a spraying system and a ground control system. The transmission system, the rotor wing system, the power device, the fuel oil system, the undercarriage, the fairing, the flight control system and the spraying system are arranged on the rack, and the fairing wraps the rack. The spraying system comprises a U-shaped pesticide box and a spraying rod, and the U-shaped pesticide box guides liquid pesticide into the spraying rod through a water pump of a gasoline engine. According to the scheme, a manned helicopter is used as a prototype and is structurally improved, the characteristic that the manned helicopter is large in load capacity is retained, the agricultural and forestal plant protection unmanned helicopter can be provided with the high-capacity U-shaped pesticide box, and therefore, the working efficiency of spraying operation of the helicopter is greatly improved.

The invention discloses a method for preparing high-quality LMW (low molecular weight) heparins. Based on an improved beta-elimination and degradation method, through innovatively adding a heavy salinization method, a polyphosphazene alkaline hydrolysis method and a saponification method and the like, the key problems that in feed liquid, more macromolecular heparins exist, and micromolecular heparins are accumulated, and the like are solved, thereby preparing super small molecular fragments. The average molecular weight of ultralow molecular heparin sodium prepared by using the method above is 2000-3000, the molecular weight distribution of the heparin sodium is as follows: the proportion of the molecular weight less than 1600 is less than or equal to 40.0%; and the proportion of the molecular weight greater than 4500 is less than or equal to 11.0%; the rate of the resistant FXa / FIIa is greater than 30, wherein the valence of the resistant FXa is 145-180 IU / mg, and the valence of the resistant FIIa is less than 5.0 IU / mg. Compared with low molecular heparin sodium and ultralow molecular heparin sodium, the high-quality LMW heparin sodium has an extremely good antithrombotic activity, a smaller bleeding risk and a lower influence on platelets, therefore, the high-quality LMW heparin sodium is expected to be a new-generation heparin antithrombotic medicament.

The invention discloses a composite scale-inhibiting corrosion-inhibiting bactericide and a preparation method thereof. The bactericide is prepared from the following raw materials in parts by weight:10-20 parts of alcohol, 20-40 parts of quaternary ammonium salt, 10-20 parts of organic sulfide, 5-10 parts of phosphonic acid salt, 5-13 parts of polymer, 5-10 parts of chlorophenol, and 10-30 partsof deionized water. The preparation method comprises the following steps: adding soft water into a reaction vessel by a pump according to metering, adding methanol or ethanol into the reaction vessel, and adding the quaternary ammonium salt, the phosphonic acid salt, the polymer, the organic sulfide, and the chlorophenol into the reaction vessel sequentially, and stirring respectively when each of the products is added; and stirring for another 30 minutes after addition of the raw materials is completed, so as to obtain a finished product. According to the composite scale-inhibiting corrosion-inhibiting bactericide and the preparation method thereof, the components have very high complementarity, synergy and compatibility, so that the medicament has excellent performance, and can effectively prevent the formation of calcium carbonate scale, calcium sulfate scale and calcium silicate scale in water; and under a medicament adding concentration of 50-100 ppm, a protective film can be formed on a tube wall, so that corrosion of equipment and piping is prevented.

The invention discloses a medicine composition for treating skin diseases. The medicine composition contains the following raw material medicines in parts by weight: 1 part of doramectin and 1-2 parts of terbinafine. The invention further provides a preparation method for the medicine composition and an application of the medicine composition in preparation for a medicine for treating skin diseases. Pharmacological experiments indicate that the medicine composition disclosed by the invention is safe and free from toxic and side effects, fast to become effective and high in effective rate, low in medication dose and low in administration frequency, as well as wide in selective dosage forms, simple in administration mode, and suitable for large-scale clinic popularization and application.

The invention provides a novel compound capable of effectively inhibiting ATX. The compound is a compound represented by formula I, or a tautomer, a stereoisomer, a hydrate, a solvate, a salt or a prodrug of the compound represented by formula I. In the formula I, R1 and R2 are independently selected from-H or-CH3, respectively, with the proviso that R1 and R2 are not-H or-CH3 at the same time.

The invention discloses asiaticoside gel dressing for external use and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. According to the invention, an original ointment is improved by combination with the properties of medicines and the characteristics of surgical local application, and the asiaticoside gel dressing for external use is prepared by taking a gel dressing as a carrier. The external hydrogel dressing is simple in prescription and process, high in water content, capable of providing a mild and moist healing environment for a wound surface, and suitable for symptoms such as burns, wounds, keloids and scleroderma.

The invention discloses an RGD-SSL lipidosome for packaging turtle shell peptide and a preparation method of the lipidosome. The turtle shell peptide long-cycle lipidosome modified by RGD comprises a lipidosome body and the turtle shell peptide (HGRFG) in the lipidosome body. The lipidosome body is prepared from egg yolk lecithin (EPC), cholesterol (Chol), mPEG2000-DSPE and RGD-PEG2000-DSPE according to the molar ratio of 50:25:1:0.6, and the weight ratio of the turtle shell peptide (HGRFG) to the EPC is 1:5 to 1:30. The defects that turtle shell peptide and other oligopeptides can easily degrade when orally taken and are low in bioavailability and short in half-life period are overcome; the RGD modified turtle shell peptide long-cycle lipidosome (RGD-SSL-turtle shell peptide) is obtained by packaging the turtle shell peptide with the granularity and RGD modified dual-control hepatic targeting lipidosome, the local biological effect and cycle half-life period are improved, the dosage frequency is reduced, and the lipidosome is suitable for treatment of hepatic fibrosis and other hepatic diseases.

The invention discloses a choroidal neovascularization targeting nanoparticle coated with a macrophage membrane and a preparation method of the choroidal neovascularization targeting nanoparticle. A polylactic acid-glycolic acid copolymer entraps rapamycin to prepare rapamycin-PLGA nanoparticles, the rapamycin-PLGA nanoparticles are used as an inner core, and a macrophage membrane is used as a capsid to coat the surface of the rapamycin-PLGA nanoparticles; wherein the mass ratio of the rapamycin to the polylactic acid-glycolic acid copolymer is 1: (9-20), and the mass ratio of the protein in the macrophage membrane to the polylactic acid-glycolic acid copolymer is 1: (1-1.5). The prepared nanoparticles are good in biocompatibility, the preparation method is simple, and the particle size distribution of the nanoparticles is uniform. The key lesion of age-related macular degeneration, namely choroidal neovascularization, is actively targeted by using biomolecules on the surface of a macrophage membrane, so that the active recruitment of a drug-containing carrier to the neovascularization is effectively improved, and the effect of protecting retinal pigment epithelium under an inflammatory condition is also achieved while the neovascularization is inhibited.

The invention provides a microsphere for double protection of antibody drug and intravitreal injection, and a preparation method thereof. Particles of a monoclonal antibody drug are prepared by adopting a method of water phase-water phase emulsification, polylactic acid-glycolic acid copolymer and polyketal are utilized as carrier materials, and a sustained release microsphere that wraps and carries the particles of a dextran-monoclonal antibody drug is prepared by employing an emulsion solvent volatilization method of water phase-oil phase-solid phase. Denaturation and aggregation of antibodies are caused by an acidic microenvironment of polylactic acid-glycolic acid in an organic phase / aqueous phase interface and a degradation process, the drug loading capacity of the microsphere is increased and a burst release phenomenon during a releasing process of the microsphere is reduced, and double protection on the monoclonal antibody drug of the microsphere is achieved; the polyketal enables the drug loading capacity of the microsphere to be increased, enables the stimulation of an acidic degradation product of the polylactic acid and glycolic acid on eye environment to be reduce, andenables side effects such as endophthalmitis to be reduced; and the microsphere can release the monoclonal antibody for not less than 28 days in the in vitro environment and for not less than 2 monthsin the eye, and so, the frequency of administration can be reduced, pain of patients and economic burden are reduced, and the compliance of patients is improved.

The invention discloses AST (astaxanthin)-supported phospholipid nanoparticles and a preparation method thereof. The phospholipid nanoparticles are obtained by mixing an organic phase in which a highmolecular polymer and astaxanthin are dissolved and a water phase in which phospholipid are dissolved by emulsion solvent volatilization, wherein the high molecular polymer is single MPEG-PLA (methoxypoly(ethylene glycol)-poly(lactide) copolymer), and phospholipid is DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine). Astaxanthin is subjected to entrapment modification of the phospholipid nanoparticles, the dissolution characteristic and size of astaxanthin are changed, and water solubility of lipid-soluble drug astaxanthin is greatly improved; meanwhile, astaxanthin is endowed with slow release characteristic by the phospholipid nanoparticles, that is, the drug is continuously and slowly released after entering cells of pathological changes, so that the administration frequency can be reduced, and the treatment effect can be enhanced.

The invention discloses an automatic medicine dispensing system. The automatic medicine dispensing system comprises an automatic medicine dispensing controller, a medicine discharging control machine,a medicine feeding device, a storage unit and an indicating unit; the medicine discharging control machine is connected with the automatic medicine dispensing controller, and a plurality of medicineslots for storing medicines are arranged in the medicine discharging control machine; the medicine feeding device is connected with the automatic medicine dispensing controller and used for placing the medicines to the corresponding medicine slots; the medicine dispensing frequency of the corresponding stored medicines in the multiple medicine slots and the medicine feeding time of the corresponding stored medicines are stored in the storage unit; and the indicating unit is connected with the automatic medicine dispensing controller and used for indicating medicine storing states of the multiple medicine slots. Time of taking out each unit of the medicines is confirmed by the automatic medicine dispensing controller according to the medicine dispensing frequency of each of the medicines, the time of taking out each unit of the medicines is compared with medicine feeding time of each of the medicines, the amount of the limit surplus medicines in the medicine slots is confirmed accordingto the match degree of the time of taking out each unit of the medicines and the medicine feeding time of each of the medicines, the indicating unit is controlled to operate indicating when the amount of medicines is less than the amount of the limit surplus medicines, and medicine feeding instructions are sent to the medicine feeding device.

The invention discloses a chitosan-oligosaccharide-modified self-carrying type carrier-free nasal cavity nano preparation brain-targeted delivery system and a preparation method thereof. The system includes hydrophobic micro-molecule drugs, polyethylene glycol derivatives and chitosan oligosaccharide which have a neuroprotective effect. The invention also provides a preparation method of the nasalcavity nano preparation brain-targeted delivery system. The preparation method includes the steps of 1, preparing nano-particle freeze-dried powder; 2, stirring the freeze-dried powder and chitosan oligosaccharide in isotonic normal saline before use to form a nasal cavity preparation with good membrane permeability. The system is simple in preparation method and can improve the hydrophobicity ofthe micro-molecule drugs, reduce the toxicity and enhance the ne neuroprotective effect. The system is free of carriers, biodegradation problems and accumulation of toxin. The drug carrying rate reaches 25 percent or above, a permeable membrane has good absorption performance after being modified by chitosan oligosaccharide, and the drugs are delivered into the brain with high targeting property.The application modes of the dosage form include nasal dripping, spray and the like, the operation is simple, convenience is provided for patients who have taken the drugs for a long time, and the system has a good application prospect in the aspect of treating nervous system diseases.

The invention discloses an in-situ hydrogel composition taking nano-micelles as a cross-linking agent and application of the in-situ hydrogel composition. The invention discloses an in-situ hydrogel composition suitable for local co-delivery of macromolecular drugs and / or micromolecular drugs and application. Functionalized micelles are used as indissolvable micromolecular solubilizing carriers and are crosslinked with a hydrophilic polymer hydrogel framework material to construct a reticular three-dimensional hydrogel structure, so that local controllable delivery and release of micromolecular drugs and biomacromolecular drugs is realized. According to the in-situ hydrogel composition, micelles with functionalized end groups are used as solubilizing carriers of indissolvable drugs to realize local controllable delivery and release of micromolecular drugs, and the functionalized end groups are used as the cross-linking agent of hydrogel to be cross-linked with a side chain functionalized modified chain hydrophilic polymer material to construct a hydrophilic reticular three-dimensional gel structure. Micromolecules for local photothermal therapy can improve the photothermal efficiency of the photothermal agent and the photothermal stability after repeated illumination effectively, and can be applied to adjuvant therapy after tumor surgery.

The invention discloses a phospholipid nanoparticle loaded with astaxanthin (AST) and a preparation method thereof. The phospholipid nanoparticle is obtained by mixing an organic phase in which a polymer and astaxanthin are dissolved with an aqueous phase in which a phospholipid is dissolved. Obtained by emulsified solvent evaporation method, in which the polymer is monomethoxypolyethylene glycol-polylactic acid (MPEG-PLA), and the phospholipid is dimyristoylphosphatidylcholine (DMPC). The invention changes the solubility and size of astaxanthin by carrying out phospholipid nanoparticles loading modification on astaxanthin, greatly improves the water solubility of fat-soluble drug astaxanthin, and at the same time, the phospholipid nanoparticles endows astaxanthin with slow-release characteristics , that is, the drug is released slowly after entering the cells of the lesion, which can reduce the frequency of administration and enhance the therapeutic effect.

The invention discloses a diphtheria toxin loaded microneedle used for scar repair, and a preparation method of the diphtheria toxin loaded microneedle. The microneedle is a hydrogel microneedle which loads diphtheria toxins. The microneedle is prepared by curing a hydrogel precursor solution mixed with the diphtheria toxin in a microneedle template. The hydrogel precursor is selected from one or more of chitosan, gelatin, silk fibroin, hyaluronic acid, sodium alginate, polyvinyl alcohol, polyethylene glycol, carboxymethyl cellulose, methacrylate gelatin, polyethylene glycol diacrylate, polylactic acid, polylactic acid-glycolic acid copolymers, polyvinylpyrrolidone and polydopamine. The diphtheria toxin loaded microneedle has the advantages of being high in permeability, simple in operation and the like, and can reduce administration frequency.

The invention discloses a bacillus thuringiensis floating sustained-release tablet. The bacillus thuringiensis floating sustained-release tablet comprises 25-45% of granulated cork 0.1-1mm in grain size, 15-40% of silicate mineral granules 0.1-1mm in grain size, 5-15% of bacillus thuringiensis israelensis active ingredient powder, 10-30% of latex, 0.1-1% of CMC-Na and 0.1-1% of antiseptic. The bacillus thuringiensis floating sustained-release tablet is capable of floating on the water stably and releasing chemicals in a sustained manner, so that lasting effect time is prolonged remarkably and the number of times of bacillus thuringiensis floating sustained-release tablet throwing is decreased.

An in-situ hydrogel composition using nanomicelle as a crosslinking agent and its application. The invention discloses an in-situ hydrogel composition and application suitable for local co-delivery of macromolecular drugs and / or small molecular drugs. Using functionalized micelles as insoluble small molecule solubilization carriers and cross-linking hydrophilic polymer hydrogel framework materials to construct network-like three-dimensional hydrogel structures to achieve locally controlled release of small molecule drugs and biomacromolecular drugs . The in-situ hydrogel composition of the present invention realizes local controllable delivery of small-molecule drugs through the terminal-functionalized micelles as solubilization carriers for insoluble drugs, and the functionalized terminal groups are used as cross-linking agents for hydrogels, Cross-linking with chain-like hydrophilic polymer materials modified by side chain functionalization to construct a hydrophilic network three-dimensional gel structure. Local administration of small molecules for photothermal therapy can effectively improve the photothermal efficiency of photothermal agents and the photothermal stability after repeated irradiation, and can be used in adjuvant therapy after tumor surgery.

The invention provides a pH sensitive fel ursi eye instant gel. 100mg of the pH sensitive fel ursi eye instant gel contains: a, 10mg of fel ursi powder extracted solution; b, 0.29 to 0.31ml of carbomer; and c, 0.45 to 0.49mg of hydroxypropyl methyl cellulose. The pH sensitive fel ursi eye instant gel is invented based on influences of eye physiology characteristics such as lacrimation and blink oninstant gel application on eyes, the contact time of medicine with eyes is prolonged, medicine administration frequency is reduced, no eye irritation is caused, and the stability is high.

The invention provides a pyrrolopyrimidine derivative and application thereof, and particularly provides a novel compound capable of effectively inhibiting ATX. The novel compound is a compound as shown in a formula (I) which is described in the specification, or a tautomer, a stereoisomer, a hydrate, a solvate, salt or a prodrug of the compound as shown in the formula (I).

The invention relates to the technical field of drag reducers, in particular to a high-efficiency drag reducer and its application method. A high-efficiency drag reducer, including A component and B component; the preparation raw material of the A component includes polyquaternium-11; the B component is an α-olefin copolymer; the B component The raw materials for preparation include long-chain alkyl methacrylate, acrylic acid, initiator, and emulsifier; the mass ratio of the A component to the B component is 1: (0.8-1.2). The high-efficiency drag reducer of the invention has strong shear resistance, which helps to reduce the turbulent flow resistance of oil products, increase the flow velocity, and improve the pipeline delivery volume.

The invention belongs to the technical field of cleaning equipment and specifically relates to an online drug cleaning device for a filtering system. The online drug cleaning device comprises a pressurizing pump, a drug cleaning device and a filter element which are serially connected with each other. The drug cleaning device is arranged on a pipeline on the front end of the filter element and isused for storing drugs and releasing drugs for cleaning the filter element under a preset condition. The online drug cleaning device provided by the invention is serially connected with a water feeding pipe of the filter element, so that dosing can be performed without influence on the filtering work; the structure design is smart; drugs can be added into mutually isolated sealed spaces; when thedrugs in one space are used up, only the drugs in another space of the same device need to be released, so that dosing times can be reduced and the drug cleaning efficiency is greatly increased.

The present invention proposes a new compound that effectively inhibits ATX, which is a compound represented by formula I, or a tautomer, stereoisomer, hydrate, solvate, salt or prodrug of the compound represented by formula I: where: R 1 and R 2 independently selected from -H or -CH 3 , provided that R 1 and R 2 Not both ‑H or not both ‑CH 3 .

The invention discloses a recombinant human TSG6-IFN alpha fusion protein, a preparation method thereof and application of the recombinant human TSG6-IFN alpha fusion protein as an antiviral drug. Thepreparation method comprises the following steps: after optimizing existing human TSG-6, porcine IFN-alpha or human IFN-alpha genes, connecting the porcine IFN-alpha or human IFN-alpha genes with thehuman TSG-6 genes through a Link connecting peptide gene fragment, cloning to a pET-32a expression vector, transforming into escherichia coli, carrying out inducible expression, and washing, denaturing and renaturing the expressed bacteria; and after separating and purifying, adding a freeze-drying protective agent, and carrying out freeze drying so as to prepare the rhTSG6-PoIFN alpha fusion protein and an rhTSG6-hIFN alpha fusion protein. The VSV virus resistance titer of the rhTSG6-PoIFN alpha fusion protein is up to (1.60+ / -0.45)*10<7>IU / mL; and the VSV virus resistance titer of the rhTSG6-hIFN alpha fusion protein is up to (4.50+ / -1.32)*10<6>IU / mL. By virtue of the method, efficient expression and batch preparation of non-naturally existing characteristic fusion proteins are achieved; and the half-life period of the recombinant human TSG6-IFN alpha fusion protein in a body is up to 60-72 hours, the antiviral effect is relatively good, and the recombinant human TSG6-IFN alpha fusion protein can be developed and applied as a novel antiviral drug.

The invention discloses a self-carrying carrier-free nasal cavity nano-preparation brain-targeted delivery system modified by chitosan oligosaccharides and a preparation method thereof. Including hydrophobic small molecule drugs with neuroprotective effects, polyethylene glycol derivatives, and chitosan oligosaccharides. The present invention also provides a preparation method for the brain-targeted delivery system of the nasal cavity nano-preparation. The first step is to prepare the freeze-dried powder of nanoparticles, and the second step is to stir the freeze-dried powder and chitosan oligosaccharide in isotonic saline before use to form a nasal cavity preparation with good membrane permeability. The preparation method of the system of the present invention is simple, can improve the hydrophobicity of small molecule drugs, reduce toxicity, and enhance neuroprotective effect; there is no carrier, no biodegradation problem and accumulation toxicity, the drug loading rate is as high as 25%, and the membrane is permeable after being modified by chitosan oligosaccharides Absorption is good, and the drug is delivered into the brain with high targeting. The administration method of the dosage form is nasal drop, spray, etc., and the operation is simple, which is convenient for patients who take medicine for a long time, and has a good application prospect in the treatment of nervous system diseases.